Clinical trial
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With…
NCT00455572 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00455572 |
|---|---|
| Title | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer |
| Official title | Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-Small Cell |
| Intervention type | Biological, Drug, Procedure |
| Interventions | Immunotherapeutic GSK1572932A, Cisplatin (CDDP), Vinorelbine, Radiotherapy |
| Enrollment | 71 |
| Start date | May 11, 2007 |
| Primary completion | Aug 4, 2013 |
| Completion | Aug 8, 2013 |
| First posted | Apr 3, 2007 |
| Last update posted | May 15, 2017 |
| Countries | Belgium, Canada, France, Germany, Italy, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: